Close X
Monday, December 23, 2024
ADVT 
Health

Researchers working on Covid vaccine that people can drink

Darpan News Desk IANS, 23 Jan, 2023 01:58 PM
  • Researchers working on Covid vaccine that people can drink

San Francisco, Jan 23 (IANS) Researchers are working on a Covid-19 vaccine that people may drink instead of receiving with a needle, expanding their focus onto mucosal vaccines, which include nasal vaccines as well as "swish and swallow" oral vaccines.

The vaccine, called QYNDR, completed its phase 1 clinical trial and is currently waiting on more funding to conduct the more detailed, advanced trials that could actually bring the vaccine to market, reports CNET.

"The QYNDR vaccine is pronounced 'kinder', because it's a softer way to deliver a vaccine," Kyle Flanigan, founder of QYNDR's maker, US Specialty Formulations, was quoted as saying.

Moreover, the report said that promising clinical trial results from New Zealand offer hope that QYNDR will be a viable option for protection against the string of Covid-19 variants circulating now.

"It's really challenging to have a vaccine survive making it through your digestive system," Flanigan said.

"We were able to figure out how to get a vaccine past the stomach and into the gut and have it be effective and induce the appropriate response," she added.

Scientists are hopeful that mucosal vaccines will not only protect against severe diseases and death, as revolutionary mRNA vaccines and boosters have but also ward off infections, the report said.

Different from traditional vaccines, mucosal vaccines enter through our mucous membranes, either through our nose (as in the much-discussed nasal Covid-19 vaccine) or through our gut (as in the orally suspended QYNDRs).

Mucosal vaccines have been supported as viable, or even preferable, options for combating Covid-19 infections due to the different types of immunity they produce and the fact that it begins right where the virus enters our bodies, the report mentioned.

MORE Health ARTICLES

ER visits down 25 per cent in early 2020: report

ER visits down 25 per cent in early 2020: report
A new report finds emergency department visits dropped by 25 per cent in the early days of the COVID-19 pandemic.

ER visits down 25 per cent in early 2020: report

UN cautions that virus plasma treatment still experimental

UN cautions that virus plasma treatment still experimental
The World Health Organization on Monday cautioned that using blood plasma from COVID-19 survivors to treat other patients is still considered an experimental therapy, voicing the concern as a U.S. boost for the treatment has many scientists afraid formal studies will be derailed.

UN cautions that virus plasma treatment still experimental

Pandemic pushes expansion of 'hospital-at-home' treatment

Pandemic pushes expansion of 'hospital-at-home' treatment
As hospitals care for people with COVID-19 and try to keep others from catching the virus, more patients are opting to be treated where they feel safest: at home.

Pandemic pushes expansion of 'hospital-at-home' treatment

Pharmacists can give childhood shots, U.S. officials say

Pharmacists can give childhood shots, U.S. officials say
Pharmacists in all 50 states are now allowed to give childhood vaccinations under a new directive aimed at preventing future outbreaks of measles and other preventable diseases.

Pharmacists can give childhood shots, U.S. officials say

Trail of bubbles leads scientists to new coronavirus clue

Trail of bubbles leads scientists to new coronavirus clue
A doctor checking comatose COVID-19 patients for signs of a stroke instead stumbled onto a new clue about how the virus may harm the lungs -- thanks to a test that used tiny air bubbles and a robot.

Trail of bubbles leads scientists to new coronavirus clue

FDA blocks much-anticipated BioMarin hemophilia gene therapy

FDA blocks much-anticipated BioMarin hemophilia gene therapy
Investors fled drug developer BioMarin in droves on Wednesday, driving shares down by a third after U.S. regulators rejected the company’s potentially game-changing hemophilia A gene therapy over concerns it might not really be a one-and-done lifetime treatment.

FDA blocks much-anticipated BioMarin hemophilia gene therapy